{
    "nct_id": "NCT06137144",
    "official_title": "A Modular Phase I/II, Open-label, Multicentre Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a PRMT5 Inhibitor, as Monotherapy and in Combination With Anticancer Agent(s) in Participants With Relapsed/Refractory Haematologic Malignancies",
    "inclusion_criteria": "Inclusion criteria\n\n* Adequate organ and bone marrow function.\n* In Part A (dose escalation), participants must be aged â‰¥ 18 years at the time of signing the informed consent. In Part B (dose optimization/expansion), participants must be at least 15 years of age.\n* Histologically confirmed documented diagnosis of r/r cHL based on criteria established by the World Health Organization\n* Must provide FFPE baseline tumour tissue to meet the minimum tissue requirement for central MTAP expression determination.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Contraceptive use by males or females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n\nModule 1 (cHL):\n\n* At least 1 radiographically measurable, and/or FDG-avid lymphoma lesion > 1.5 cm.\n* Participants must have documented r/r active disease, must have previously received at least 3 prior lines of therapy (including Brentuximab Vedotin and anti-PD-1 therapy) for the treatment of cHL, and must have exhausted all available therapies with demonstrated clinical benefit.\n\nExclusion criteria\n\n* Any significant laboratory finding or any severe and uncontrolled medical condition.\n* Active CNS involvement by lymphoma, leptomeningeal disease, or spinal cord compression.\n* Serologic active HBV or HCV infection.\n* Known to have tested positive for HIV.\n* Active gastrointestinal disease or other condition that will interfere with oral therapy.\n* Any of the following cardiac criteria:\n\n  * Mean resting QTcF > 470 msec or clinically important abnormalities in rhythm (ventricular arrhythmias and uncontrolled atrial fibrillation)\n  * Factors that increase the risk of QTc prolongation or risk of arrhythmic events\n  * Cardiac procedures or conditions within the last 6 months: Coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI) or heart valve intervention vascular stent implantation, acute coronary syndrome / myocardial infarction, uncontrolled angina pectoris, use of therapeutic anti-coagulation for treatment of active thromboembolic events.\n  * Severe valvular heart disease\n  * Congestive heart failure Grade II to Grade IV\n  * Prior or current cardiomyopathy\n  * Uncontrolled hypertension\n  * Brain perfusion problems such as haemorrhagic or thrombotic stroke (including transient ischemic attacks)\n* Unresolved non-haematological toxicities of Grade > 1 from prior anticancer therapy (excluding peripheral neuropathy, vitiligo, alopecia, and endocrine disorders that are controlled with replacement hormone therapy, and asymptomatic laboratory abnormalities), unless immune-mediated.\n* History of another primary malignancy.\n* History of significant haemoptysis or haemorrhage within 4 weeks of the first dose of study treatment.\n* Requires ongoing immunosuppressive therapy, including systemic corticosteroids.\n* Prior treatment with a MAT2A inhibitor or a PRMT5 inhibitor.\nHealthy volunteers allowed\nMust have minimum age of 15 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}